With the recent recommendation to approve a new gene therapy aimed at leukemia and lymphoma, the national media is buzzing about what this means for a host of other diseases and technologies. It wasn’t long ago that “gene therapy” represented the flaws and dangers of re-engineering genes and immune systems to fight disease. Throughout its hiatus, researchers have been working on a host of safer, more effective techniques resulting in potential treatments for blindness, hemophelia, and CALD. While we may be at the dawn of a new era of medicine, it is difficult to predict the market reaction, given the six-figure price tag of these therapies. There are also questions about the long term side effects. In addition to the gene therapy or gene “silencing” markets, there is a similar mad dash happening in the gene editing or “CRISPR” markets. These technologies hold the promise to eliminate genetic diseases like Huntington’s disease and some forms of cancer. Yet, with all this potential, we are rapidly approaching an ethical line that was recently only in the minds of science fiction writers.
On Wednesday, MIS2017 attendees will a close look at how the front line experts are simultaneously navigating the science, the markets, and the ethical questions of these technologies. Register today to join us.
Destiny Changing Technologies: Making Sense of Gene Therapy, Gene Silencing, and Gene Editing Markets
October 25, 2017 | 10:15am – 11:05am
Is gene therapy making a comeback? Will we really be editing genes? These seemlingly science-fiction approaches are already being used to treat diseases. Experts on this panel will look at the tremendous business opportunities and ethics surrounding CRISPR and Gene Therapy, while also looking at what these new powers could mean for humanity.
Casey Cunningham, MD, Chief Scientific Officer, Santé Ventures
Katrine Bosley, CEO, Editas Medical
Michael Severino, MD, EVP, R&D, Chief Scientific Officer, AbbVie
Akshay Vaishnaw, MD, PhD, EVP, R&D, Alnylam